Market Currents
K-V Pharmaceutical (KV.A +22%) soars following a brief halt after it says information from two...
-
Thursday, October 13, 2011, 1:21 PM ETK-V Pharmaceutical (KV.A +22%) soars following a brief halt after it says information from two distinguished medical research bodies confirm that its FDA-approved Makena and unapproved compounded 17P formulations are not identical. The update clears previous concerns that were used by insurers to deny coverage for Makena prescriptions.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
